Key result
Multimodality treatment consisting of chemotherapy, surgery, and radiotherapy has improved five-year survival rates from 5-10% to 40% in adult patients with Ewing sarcoma.
Advances in multidisciplinary treatment, including combined chemotherapy, surgery, and radiotherapy, have significantly improved quality of life and prognosis for patients with Ewing sarcoma.
Answers are grounded in this paper and cite their sources.
Supports multimodality therapy for adults with Ewing sarcoma; leaves open optimal regimens and prospective validation.
Ewing sarcoma is a group of low-differentiated, high-grade, small-cell tumours. It is the third most common malignancy among primary bone tumours in adults. The prognosis of Ewing sarcoma is bad, and very often at the time of diagnosis the disease is highly advanced. For patients with localized disease, who have no metastases diagnosed at baseline, it is necessary to use combined treatment. It consists of induction chemotherapy (12–18 weeks) + local treatment (surgery ± radiotherapy or radiotherapy), and is followed by adjuvant consolidation chemotherapy. The whole treatment takes about 48–52 weeks. Advances in multidisciplinary treatment, including combined chemotherapy, surgery and radiotherapy have resulted in a significant improvement in patients’ quality of life and prognosis. Clinical trials are currently underway and new treatment standards are being developed.
No takes yet. Share an insight, caveat, or question.
Świtaj et al. (2019) conducted a review in Ewing sarcoma. Multimodality treatment was evaluated. Multimodality treatment consisting of chemotherapy, surgery, and radiotherapy has improved five-year survival rates from 5-10% to 40% in adult patients with Ewing sarcoma.
Synapse has enriched 10 related papers. Consider them for comparative context: